



Ali, S. R., Ozdemir, B. A., & Hinchliffe, R. J. (2018). Critical appraisal of the quality of evidence addressing the diagnosis, prognosis, and management of peripheral artery disease in patients with diabetic foot ulceration. *European Journal of Vascular and Endovascular Surgery*, 56(3), 401-408. <https://doi.org/10.1016/j.ejvs.2018.05.009>

Peer reviewed version

License (if available):
CC BY-NC-ND

Link to published version (if available):
[10.1016/j.ejvs.2018.05.009](https://doi.org/10.1016/j.ejvs.2018.05.009)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at <https://www.sciencedirect.com/science/article/pii/S1078588418303034?via%3Dihub#!>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Critical appraisal of the quality of evidence addressing the diagnosis, prognosis and management of peripheral artery disease in patients with diabetic foot ulcers

Stephen R. Ali MMedSc(Hons) PGCME MRCS(Eng), Baris A. Ozdemir BSc PhD FRCS, Robert J. Hinchliffe MD FRCS

Stephen.Ali@nbt.nhs.uk

drbaozdemir@gmail.com

Robert.Hinchliffe@nbt.nhs.uk

Bristol Centre for Surgical Research, University of Bristol, Bristol, UK

Corresponding author:

Stephen Ali; Stephen.Ali@nbt.nhs.uk; Department of Vascular Surgery, North Bristol NHS Trust, Southmead Hospital, Southmead Road, Bristol, BS10 5NB; 0117 4140798.

Abstract

Aims: There is a paucity of robust evidence on the prevention and management of diabetic foot ulcers (DFU's) to inform treatment. This study appraises the current quality of the evidence addressing the diagnosis, prognosis and management of peripheral artery disease (PAD) in patients with DFU's using a newly devised 21-point (TOP) disease-specific research appraisal tool published by the International Working Group on the Diabetic Foot (IWGDF) and European Wound Management Association.

Methods: The 2015 IWGDF guidance on diagnosis, prognosis, and management of PAD in patients with DFU's was used to identify studies pertaining to prevention and management. Two reviewers assessed these articles against the TOP checklist which examines study design, conduct and outcome reporting.

Results: Overall median score was 8 (3-12) out of 21. Median design total score was 2 (0-4) out of 11. Median conduct total score was 2(1-4) out of 6. Median outcomes total score was 3 (1-4) out of 4. There was improvement with time in overall total (Spearman Rho 0.39, $p=0.0005$), design total (0.35, $p=0.0023$), outcomes total (0.35, $p=0.0002$) but not conduct total (-0.03, $p=0.8132$) scores.

Conclusions: Whilst this analysis revealed an improvement over time in the overall calibre of studies, the present quality remains poor.

Introduction

The International Diabetes Federation project that the global prevalence of diabetes mellitus is set to rise to approximately 600 million by 2035.¹ Foot ulcers complicating diabetes are burdensome for patients and costly for society. There is a paucity of robust evidence on the prevention and management of diabetic foot ulcers (DFU's) to inform treatment, leading to calls for higher quality research from recently published systematic reviews.^{2, 3, 4, 5, 6, 7} As a consequence *Jeffcoate et al. 2016* produced a 21-point (TOP) checklist on behalf of the International Working Group on the Diabetic Foot (IWGDF) and the European Wound Management Association (EWMA) both highlighting and addressing the shortcomings of existing appraisal methodologies. This checklist integrates the exigencies of diabetic foot reporting standards into a single disease specific research appraisal tool.⁸ TOP summarises details that should be included in study design, conduct, and reporting for publications addressing prevention and management of DFU's. The ultimate goal is of course that the research community will adopt the specified criteria into future reports to improve reporting standards. To date no study has examined the utility or validity of the TOP checklist in assessing the current quality of published work on DFU's.

The aim of this study was to appraise the current quality of the evidence addressing the diagnosis, prognosis and management of peripheral artery disease (PAD) in patients with DFU's using the TOP checklist. The IWGDF has been publishing and updating international guidelines on the prevention and management of foot problems in diabetes since 1999 based upon best available evidence. We decided to use IWGDF guidance as a source of original research to examine the current quality of reporting standards in the diabetic foot ulcer literature.

Methodology

We utilised the 2015 IWGDF guidance on diagnosis, prognosis, and management of PAD in patients with foot ulcers in diabetes to identify studies pertaining to the prevention and management of

DFU.¹⁰ Within this document are cited three systematic reviews that summarise the literature, all conforming to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance.¹¹ Using the studies cited by Hinchliffe *et al.* 2016 ($n = 57$), Brownrigg *et al.* 2016 ($n = 10$) and Brownrigg *et al.* 2016 ($n = 11$) we identified a total of 78 original research articles to be assessed in our study.^{4, 12, 13} We categorised studies into case series, cross-sectional studies, cohort studies and randomised trials.

We used the TOP scoring system to assess the quality of published work cited within the systematic reviews. Three broad areas of study design, study conduct and outcome reporting were assessed according to this checklist with a maximum score of 11, 6 and 4 respectively. For non-randomised studies it was not possible to score in some domains of the TOP checklist by virtue of the deficiencies in their design.

Scoring was performed by two independent assessors (S.R.A. and B.A.O.). When conflict did arise a third, senior author (R.J.H.) was consulted and an agreement reached. Descriptive data analysis was performed using Microsoft Excel 2010® (Microsoft Cooperation, Redmond, Washington USA) and statistical analysis performed using R 3.1.1 (R Core Team, R Foundation for Statistical Computing, Vienna, Austria).

Medians are reported alongside range. The change in score by year of publication was tested using Spearman's rank correlation coefficient, which is a non-parametric measure of rank correlation, and $p < 0.05$ was considered statistically significant.

Results

The most common study design was case series ($n = 54$), followed by cohort study ($n = 19$) and cross-sectional study ($n = 5$). There were no randomised trials.

The overall (total) median score was 8 (3-12) out of 21. The median design total score was 2 (0-4) out of 11. The median conduct total score was 2 (1-4) out of 6. The median outcomes total score was 3 (1-4) out of 4.

Over the period of the analysis there was improvement with time in the overall total (Spearman Rho 0.39, $p=0.0005$), design total (0.35, $p=0.0023$), outcomes total (0.35, $p=0.0002$) but not the conduct total (-0.03 , $p=0.8132$) scores. Figure 1 demonstrates however that the improvements for the overall and design total though statistically significant hide the fact that the overall quality of studies remains poor.

Table 1 lists and summarises the results for each item in the TOP scoring system. With regards to items addressing study design, only 21% of studies used appropriate definitions for “ulcer”, “healing”, and all other aspects of the population studied and their outcomes. The quality of reporting for this item did improve over the course of the study (Spearman Rho 0.35, $p=0.0015$). Only 17% of studies chose a primary outcome of direct clinical relevance. No studied randomised or blinded the researchers, clinicians or participants. Only one study performed an appropriate sample size calculation.¹⁴

15% of studies documented the primary outcome in 75% or more of participants whilst 5% analysed the results primarily by intention to treat analysis.

The reporting of outcomes was judged to be more robust except that only 51% of studies discussed the important strengths and weaknesses of the study, though this did improve over the course of the analysis (Spearman Rho 0.44, $p>0.0001$).

Except for the two items already highlighted no other individual item demonstrated a significant improvement over the course of the analysis.

Discussion

Improvement with time

There has been modest improvement with time in the reporting of study design and outcomes, leading to improvements in the overall total TOPS score. The improvements in study design reflect moderate improvements in the use of appropriate definitions for key aspects of the population and outcome as well as for the detail with which studies were described. The improvements in study outcome reporting largely reflect an improvement in the description of study strengths and weaknesses over time. These improvements may reflect the introduction of guidelines for reporting observational studies such as STROBE.¹⁵ It must be emphasised that the reporting for the majority of items listed in TOPS did not improve over time. This probably reflects a failure of authors to accommodate the multifactorial aetiology of foot ulceration in patients with diabetes, nor their multidisciplinary management.

Overall poor quality

Whilst this analysis revealed an improvement over time in the overall calibre of studies addressing the diagnosis, prognostication and revascularisation of patients with diabetes and PAD, the present quality remains poor. This is particularly true for the design and conduct of studies. This is attributable to a number of factors which we discuss here.

Poor quality of design and conduct

Studies to date have failed to address the issue of heterogeneity of patients with DFU's. It is very difficult from the present literature to ascertain the impact of current management strategies as very few studies have used appropriate definitions of ulcer and PAD severity or healing.¹⁶⁻³¹ Future analysis will need to stratify patients by severity and use more robust measures of outcome to improve the external validity of studies.

Interventions as part of PAD management in patients with DFU's are inevitably given in conjunction with other components of care such as ulcer offloading footwear, dressings, antimicrobials and pharmacological regimes. These vital components need to be accounted for in trial design and to be adequately described for external validity and to facilitate critical appraisal of comparative data. A common observation throughout the analysis was that very few authors reported these other components of care.^{16, 18, 19, 23, 25, 26, 32-42}

It is common research practise to define primary outcome at the time of study design to reduce the risk of type I error resulting from the statistical testing of many outcomes and type II error by providing the basis for a sample size calculation and an adequately powered study. Primary outcome measures were infrequently documented in the studies examined, compromising the internal validity of and the conclusions which can be gleaned from these reports.^{14, 17, 20-22, 34, 43-49}

Given that there were no randomised studies included in the analysis, features of this specific trial design (control group, independent randomisation, blinding and control group performance), that account for 19% of the total TOPS checklist as markers of good quality, could not be awarded in any case. The paucity of these hallmarks of trial quality highlight the overall need for RCT's in the DFU literature.

Diagnosis

Non-invasive tests for the detection of PAD among individuals with diabetes help to estimate the risk of amputation, ulceration, wound healing and the presence of cardiovascular disease. Despite this rationale, there is no evidence to support a single non-invasive diagnostic test for PAD detection across the spectrum of patients with diabetes.⁴ Diagnostic performance varies according to populations studied and a poor description of these cohorts in the literature limits the applicability of any findings to a particular patient group.⁴ Standardized reporting would establish comparative

datasets to identify which test(s) can best identify PAD assisting in diagnosis, prognostication and management of diabetic foot complications and cardiovascular risk.

Screening tests for PAD can help to identify patients at higher risk of ulceration and most importantly those at greater risk of amputation when tissue loss is already established.⁴ Particularly in this latter group the majority of the literature again fails to stratify patients according to disease severity (neuropathy, ulcer classification etc.) and therefore the differential utility of each test in the various strata is unclear.^{42, 50-56}

Prognostication

There is a consensus that PAD is associated with poor outcome in DFU, however the exact PAD characteristics which correlate with a poor outcome is unknown.¹² PAD is variable in its distribution and severity with a tendency of diabetic patients to have diffuse and distal disease with a greater prevalence of medial sclerosis and poor collateral formation. We need to address the clinically important questions of whether it is possible to identify specific characteristics of PAD that predict a poor outcome, at which point in the disease natural history is revascularization is needed to prevent a poor outcome, or whether there is a group of patients in whom a poor outcome is likely regardless of revascularization. In the current analysis of prognostic studies only six studies included appropriate definitions for the terms “ulcer”, “healing” and all other required aspects of the population and the outcomes.²⁴⁻²⁹ The development of a registry to standardize data collection addressing the poor quality of evidence currently available, would help to determine which demographic, comorbidity, ulcer-related and PAD factors predict failure to heal. Standardisation of data collection and reporting would allow comparisons of practice and outcome across research sites to maximizing precision, whilst accounting for heterogeneity and allowing adjusted for potential confounding factors.

Treatment

Much of the literature focuses on procedure specific (technical success, re-stenosis, target lesion revascularisation) instead of disease specific (wound healing, major amputation) or clinical (amputation free survival) outcome measures. Specifically only 17% of studies defined a primary outcome of direct clinical relevance. Future study designs should address this discrepancy and ensure that appropriately sized studies powered to detect clinically relevant differences are undertaken.

There are no studies addressing the effectiveness of revascularisation versus best medical and wound therapy alone in patients with diabetes related foot ulceration. Whilst it is unlikely such a trial would ever be conducted more robust stratification of patients in observational studies could allow a comparison of successfully and unsuccessfully revascularised patients according to disease severity. Randomised trials comparing the various revascularisation strategies are warranted and it is important that these are conducted on or robust sub-group analysis performed in patients with diabetes.

Limitations

We acknowledge that the creation of the TOPS checklist was based upon expert opinion from IWGDF members. Delphi consensus would have been the gold standard methodology to produce a recognised validated appraisal tool. There is very little robust methodology in the vascular surgery literature that considers validating disease specific appraisal tools and none specifically centred on reporting standards. However, Delphi consensus methodology has been successfully used to develop and adopt a core outcome sets for use in colorectal cancer surgical trials and research and also audit studies in reconstructive breast surgery.^{57, 58}

We selected the evidence addressing the diagnosis, prognosis and management of PAD in patients DFU's as a surrogate of the overall quality of reporting standards in the DFU literature. We recognise that including all of the IWGDF group's systematic reviews would have comprehensively appraised

the entirety of the DFU literature to provide an analysis representative of the other preventative and treatment modalities.

Conclusion

This study appraised the quality of reporting in the literature surrounding the diagnosis, prognosis and management of PAD in patients with DFU's using the TOP checklist. Future work should focus on validating the TOP checklist not only for its use in PAD but also for studies examining prevention of foot ulcers in at-risk patients, footwear and offloading to prevent and heal foot ulcers, diagnosis and management of foot infections in persons with diabetes as well as interventions to enhance healing of chronic DFU's. The TOP checklist focuses on reporting standards and incorporates aspects on outcome reporting as markers of good quality. Ultimately, the DFU research community should aspire to achieve a core outcome dataset as described by our colleagues in colorectal and breast reconstruction surgery. Only then would we be able to truly compare results from individual studies having diminished the marked heterogeneity in reporting observed in this analysis. The ultimate aim is to be able to stratify the DFU patient population in such a way as to be able to select and target treatments to the most appropriate subgroup.

References

1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes research and clinical practice*. 2014 Feb 28;103(2):137-49.
2. van Netten JJ, Price, PE, Lavery, LA..., and for the International Working Group on the Diabetic Foot (IWGDF). Prevention of foot ulcers in the at-risk patient with diabetes: a systematic review. *Diabetes Metab Res Rev*. 2016; 32: 84–98.
3. Bus, SA, van Deursen, RW, Armstrong, DG, Lewis, JE, Caravaggi, CF, Cavanagh, PR, and for the International Working Group on the Diabetic Foot (IWGDF). Footwear and offloading interventions to prevent and heal foot ulcers and reduce plantar pressure in patients with diabetes: a systematic review. *Diabetes Metab Res Rev*. 2016; 32: 99–118.
4. Brownrigg JR, Hinchliffe RJ, Apelqvist J, Boyko EJ, Fitridge R, Mills JL, Reekers J, Shearman CP, Zierler RE, Schaper NC. Effectiveness of bedside investigations to diagnose peripheral artery disease among people with diabetes mellitus: a systematic review. *Diabetes/metabolism research and reviews*. 2016 Jan 1;32(S1):119-27.
5. Hinchliffe, RJ, Brownrigg, JR, Andros, G..., and for the International Working Group on the Diabetic Foot (IWGDF). Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review. *Diabetes Metab Res Rev*. 2016; 32: 136–144
6. Peters, EJ, Lipsky, BA, Aragón-Sánchez, J..., and for the International Working Group on the Diabetic Foot (IWGDF). Interventions in the management of infection in the foot in diabetes: a systematic review. *Diabetes Metab Res Rev*. 2016; 32: 145–153
7. Game, FL, Apelqvist, J, Attinger, C..., and for the International Working Group on the Diabetic Foot (IWGDF). Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: a systematic review. *Diabetes Metab Res Rev*. 2016; 32: 154–168.

8. Jeffcoate WJ, Bus SA, Game FL, Hinchliffe RJ, Price PE, Schaper NC, International Working Group on the Diabetic Foot, European Wound Management Association. Reporting standards of studies and papers on the prevention and management of foot ulcers in diabetes: required details and markers of good quality. *The Lancet Diabetes & Endocrinology*. 2016 Sep 30;4(9):781-8.
9. Bakker K, Apelqvist J, Lipsky BA, Van Netten JJ, Schaper NC. The 2015 IWGDF guidance documents on prevention and management of foot problems in diabetes: development of an evidence-based global consensus. *Diabetes/metabolism research and reviews*. 2016 Jan 1;32(S1):2-6.
10. Hinchliffe RJ, Brownrigg JR, Apelqvist J, Boyko EJ, Fitridge R, Mills JL, Reekers J, Shearman CP, Zierler RE, Schaper NC. IWGDF guidance on the diagnosis, prognosis and management of peripheral artery disease in patients with foot ulcers in diabetes. *Diabetes/metabolism research and reviews*. 2016 Jan 1;32(S1):37-44.
11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med*. 2009 Jul 21;6(7):e1000100.
12. Brownrigg JR, Hinchliffe RJ, Apelqvist J, Boyko EJ, Fitridge R, Mills JL, Reekers J, Shearman CP, Zierler RE, Schaper NC. Performance of prognostic markers in the prediction of wound healing or amputation among patients with foot ulcers in diabetes: a systematic review. *Diabetes/metabolism research and reviews*. 2016 Jan 1;32(S1):128-35.
13. Hinchliffe RJ, Andros G, Apelqvist J, et al. Effectiveness of revascularisation of the ulcerated foot in patients with diabetes and peripheral arterial disease: a systematic review. *Diabetes/Metabolism Research and Reviews*. 2015 doi:10.1002/ dmrr.2705.

14. Malmstedt J, Leander K, Wahlberg E, Karlström L, Alfredsson L, Swedenborg J. Outcome after leg bypass surgery for critical limb ischemia is poor in patients with diabetes: a population-based cohort study. *Diabetes Care*. 2008 May;31(5):887-92.
15. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, Strobe Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *International Journal of Surgery*. 2014 Dec 31;12(12):1495-9.
16. Alexandrescu V, Hubermont G, Philips Y, Guillaumie B, Ngongang Ch, Coessens V, Vandenbossche P, Coulon M, Ledent G, Donnay JC. Combined primary subintimal and endoluminal angioplasty for ischaemic inferior-limb ulcers in diabetic patients: 5-year practice in a multidisciplinary 'diabetic-foot' service. *Eur J Vasc Endovasc Surg*. 2009 Apr;37(4):448-56.
17. Faglia E, Mantero M, Caminiti M, Caravaggi C, De Giglio R, Pritelli C, Clerici G, Fratino P, De Cata P, Dalla Paola L, Mariani G, Poli M, Settembrini PG, Sciangula L, Morabito A, Graziani L. Extensive use of peripheral angioplasty, particularly infrapopliteal, in the treatment of ischaemic diabetic foot ulcers: clinical results of a multicentric study of 221 consecutive diabetic subjects. *J Intern Med*. 2002;252:225-32
18. Faglia E, Dalla Paola L, Clerici G, Clerissi J, Graziani L, Fusaro M, Gabrielli L, Losa S, Stella A, Gargiulo M, Mantero M, Caminiti M, Ninkovic S, Curci V, Morabito A. Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. *Eur J Vasc Endovasc Surg*. 2005 Jun;29(6):620-7.
19. Faglia E, Clerici G, Clerissi J, Gabrielli L, Losa S, Mantero M, Caminiti M, Curci V, Quarantiello A, Lupattelli T, Morabito A. Long-term prognosis of diabetic patients with critical limb ischemia: a population-based cohort study. *Diabetes Care*. 2009 May;32(5):822-7.

20. Gargiulo M, Maioli F, Ceccacci T, Morselli-Labate AM, Faggioli G, Freyrie A, Giovanetti F, Testi G, Muccini N, Stella A. What's next after optimal infrapopliteal angioplasty? Clinical and ultrasonographic results of a prospective single-center study. *J Endovasc Ther*. 2008 Jun;15(3):363-9.
21. Hering J, Angelkort B, Keck N, Wilde J, Amann B. Long-term outcome of successful percutaneous transluminal angioplasty of the fibular artery in diabetic foot syndrome and single-vessel calf perfusion depends on doppler wave pattern at the forefoot. *Vasa*. 2010 Feb;39(1):67-75.
22. Acín F, Varela C, López de Maturana I, de Haro J, Bleda S, Rodríguez-Padilla J. Results of infrapopliteal endovascular procedures performed in diabetic patients with critical limb ischemia and tissue loss from the perspective of an angiosome-oriented revascularization strategy. *Int J Vasc Med* 2014; 2014: 270539.
23. Söderström M¹, Albäck A, Biancari F, Lappalainen K, Lepäntalo M, Venermo M. Angiosome-targeted infrapopliteal endovascular revascularization for treatment of diabetic foot ulcers. *J Vasc Surg* 2013; 57: 427–35.
24. Elgzyri T, Larsson J, Nyberg P, Thorne J, Eriksson KF, Apelqvist J. Early revascularization after admittance to a diabetic foot centre affects the healing probability of ischemic foot ulcer in patients with diabetes. *Eur J Vasc Endovasc Surg* 2014.
25. Elgzyri T, Larsson J, Thörne J, Eriksson KF, Apelqvist J. Outcome of ischemic foot ulcer in diabetic patients who had no invasive vascular intervention. *European Journal of Vascular and Endovascular Surgery*. 2013 Jul 31;46(1):110-7.
26. Bunt TJ, Holloway A. TcPO₂ as an accurate predictor of therapy in limb salvage. *Ann Vasc Surg* 1996; 10: 224–227.
27. Brechow A, Slesaczek T, Munch D, et al. Improving major amputation rates in the multicomplex diabetic foot patient: focus on the severity of peripheral arterial disease. *Ther Adv Endocrinol Metabol* 2013; 4: 83–94.

28. Gershater MA, Londahl M, Nyberg P, et al. Complexity of factors related to outcome of neuropathic and neuroischaemic/ischaemic diabetic foot ulcers: a cohort study. *Diabetologia* 2009; 52: 398–407.
29. Tsai CY, Chu SY, Wen YW, et al. The value of Doppler waveform analysis in predicting major low extremity amputation among dialysis patients treated for diabetic foot ulcers. *Diabetes Res Clin Pract* 2013; 100: 181–188.
30. Clairotte C, Retout S, Potier L, et al. Automated ankle-brachial pressure index measurement by clinical staff for peripheral arterial disease diagnosis in nondiabetic and diabetic patients. *Diabetes Care* 2009; 32(7): 1231–6.
31. Ezio F, Giacomo C, Maurizio C, Antonella Q, Vincenzo C, Francesco S. Evaluation of feasibility of ankle pressure and foot oxymetry values for the detection of critical limb ischemia in diabetic patients. *Vasc Endovascular Surg* 2010; 44(3): 184–189.
32. Dosluoglu HH, Cherr GS, Lall P, Harris LM, Dryjski ML. Peroneal artery-only runoff following endovascular revascularizations is effective for limb salvage in patients with tissue loss. *J Vasc Surg*. 2008 Jul;48(1):137-43
33. Dorweiler B, Neufang A, Schmiedt W, Oelert H. Pedal arterial bypass for limb salvage in patients with diabetes mellitus. *Eur J Vasc Endovasc Surg*. 2002 Oct;24(4):309-13.
34. Ferraresi R, Centola M, Ferlini M, Da Ros R, Caravaggi C, Assaloni R, Sganzeroli A, Pomidossi G, Bonanomi C, Danzi GB. Long-term outcomes after angioplasty of isolated, below-the-knee arteries in diabetic patients with critical limb ischaemia. *Eur J Vasc Endovasc Surg*. 2009 Mar;37(3):336-42.
35. Pomposelli FB Jr, Marcaccio EJ, Gibbons GW, Campbell DR, Freeman DV, Burgess AM, Miller A, LoGerfo FW. Dorsalis pedis arterial bypass: durable limb salvage for foot ischemia in patients with diabetes mellitus. *J Vasc Surg*. 1995 Mar;21(3):375-84.

36. Pomposelli FB, Kansal N, Hamdan AD, Belfield A, Sheahan M, Campbell DR, Skillman JJ, Logerfo FW. A decade of experience with dorsalis pedis artery bypass: analysis of outcome in more than 1000 cases. *J Vasc Surg.* 2003 Feb;37(2):307-15.
37. Tannenbaum GA, Pomposelli FB Jr, Marcaccio EJ, Gibbons GW, Campbell DR, Freeman DV, Miller A, LoGerfo FW. Safety of vein bypass grafting to the dorsal pedal artery in diabetic patients with foot infections. *J Vasc Surg.* 1992 Jun;15(6):982-8.
38. Taylor LM Jr, Porter JM. The clinical course of diabetics who require emergent foot surgery because of infection or ischemia. *J Vasc Surg.* 1987 Nov;6(5):454-9.
39. Kabra A, Suresh KR, Vivekanand V, Vishnu M, Sumanth R, Nekkanti M. Outcomes of angiosome and non-angiosome targeted revascularization in critical lower limb ischemia. *J Vasc Surg* 2013; 57: 44–9.
40. Alexandrescu V, Vincent G, Azdad K, et al. A reliable approach to diabetic neuroischemic foot wounds: below-the-knee angiosome-oriented angioplasty. *J Endovasc Ther* 2011; 18: 376–87.
41. Kalani M, Ostergren J, Brismar K, Jorreskog G, Fagrell B. Transcutaneous oxygen tension and toe pressure as predictors for outcome of diabetic foot ulcers. *Diabetes Care* 1999; 22: 147–151.
42. Liu F, Shen J, Zhao J, et al. Cystatin C: a strong marker for lower limb ischemia in Chinese type 2 diabetic patients? *PLoS One* 2013; 8(7): e66907.
43. Bargellini I, Petrucci P, Scatena A, Cioni R, Cicorelli A, Vignali C, Rizzo L, Piaggese A, Bartolozzi C. Primary infrainguinal subintimal angioplasty in diabetic patients. *Cardiovasc Intervent Radiol.* 2008 Jul-Aug;31(4):713-22.
44. Gibbons GW, Burgess AM, Guadagnoli E, Pomposelli FB Jr, Freeman DV, Campbell DR, Miller A, Marcaccio EJ Jr, Nordberg P, LoGerfo FW. Return to wellbeing and function after infrainguinal revascularization. *J Vasc Surg.* 1995 Jan;21(1):35-44.
45. Isaksson L, Lundgren F. Prognostic factors for failure of primary patency within a year of bypass to the foot in patients with diabetes and critical ischaemia. *Eur J Surg.* 2000 Feb;166(2):123-8.

46. Kandzari DE, Kiesz RS, Allie D, Walker C, Fail P, Ramaiah VG, Cardenas J, Vale J, Chopra A, Gammon RS. Procedural and clinical outcomes with catheter-based plaque excision in critical limb ischemia. *J Endovasc Ther*. 2006 Feb;13(1):12-22.
47. Uccioli L, Gandini R, Giurato L, Fabiano S, Pampana E, Spallone V, Vainieri E, Simonetti G. Long-term outcomes of diabetic patients with critical limb ischaemia followed in a tertiary referral diabetic foot clinic. *Diabetes Care*. 2010 May;33(5):977-82.
48. Werneck CC, Lindsay TF. Tibial angioplasty for limb salvage in high-risk patients and cost analysis. *Ann Vasc Surg*. 2009 Sep-Oct;23(5):554-9.
49. Park SW, Kim JS, Yun IJ, et al. Clinical outcomes of endovascular treatments for critical limb ischemia with chronic total occlusive lesions limited to below-the-knee arteries. *Acta Radiol* 2013; 54: 785–9.
50. Zhang H, Li XY, Si YJ, et al. Manifestation of lower extremity atherosclerosis in patients with high ankle-brachial index. *Br J Diabetes Vasc Dis* 2009; 9(4): 160–4.
51. Premalatha G, Ravikumar R, Sanjay R, et al. Comparison of colour duplex ultrasound and ankle-brachial pressure index measurements in peripheral vascular disease in type 2 diabetic patients with foot infections. *J Assoc Physicians India* 2002; 50: 1240–4.
52. Parameswaran GI, Brand K, Dolan J. Pulse oximetry as a potential screening tool for lower extremity arterial disease in asymptomatic patients with diabetes mellitus. *Arch Intern Med* 2005; 165(4): 442–6.
53. Lewis JEA, Owens DR. The pulse volume recorder as a measure of peripheral vascular status in people with diabetes mellitus. *Diabetes Tech Therapeutics* 2010; 12: 75–82.
54. Williams DT, Harding KG, Price P. An evaluation of the efficacy of methods used in screening for lower-limb arterial disease in diabetes. *Diabetes Care* 2005; 28(9): 2206–10.

55. Aboyans V, Ho E, Denenberg JO, et al. The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and nondiabetic subjects. *J Vasc Surg* 2008; 48(5): 1197–203.
56. Vogelberg KH, Stork W. Measurement of pulse reappearance time in diagnosis of peripheral vascular disease in diabetes. *Diabetes Care* 1998; 11: 345–350.
57. McNair AG, Whistance RN, Forsythe RO, Macefield R, Rees J, Pullyblank AM, Avery KN, Brookes ST, Thomas MG, Sylvester PA, Russell A. Core outcomes for colorectal cancer surgery: a consensus study. *PLoS medicine*. 2016 Aug 9;13(8):e1002071.
58. Potter S, Holcombe C, Ward JA, Blazeby JM. Development of a core outcome set for research and audit studies in reconstructive breast surgery. *British Journal of Surgery*. 2015 Oct 1;102(11):1360-71.
59. AhChong AK, Chiu KM, Wong MW, Hui HK, Yip AW. Diabetes and the outcome of infrainguinal bypass for critical limb ischaemia. *ANZ J Surg*. 2004 Mar;74(3):129-33.
60. Apelqvist J, Elgzyri T, Larsson J, Londahl M, Nyberg P, Thorne J. Factors related to outcome of neuroischemic/ischemic foot ulcer in diabetic patients. *J Vasc Surg* 2011; 53: 1582–8.
61. Clairotte C, Retout S, Potier L, et al. Automated ankle-brachial pressure index measurement by clinical staff for peripheral arterial disease diagnosis in nondiabetic and diabetic patients. *Diabetes Care* 2009; 32(7): 1231–6.
62. Davidson JT 3rd, Callis JT. Arterial reconstruction of vessels in the foot and ankle. *Ann Surg*. 1993 Jun;217(6):699-708.
63. Faris I, Duncan H. Skin perfusion pressure in the prediction of healing in diabetic patients with ulcers or gangrene of the foot. *J Vasc Surg* 1985; 2: 536–40.
64. Hertzner NR, Bena JF, Karafa MT. A personal experience with the influence of diabetes and other factors on the outcome of infrainguinal bypass grafts for occlusive disease. *J Vasc Surg*. 2007 Aug;46(2):271-279

65. Holstein P, Lassen NA. Healing of ulcers on the feet correlated with distal blood pressure measurements in occlusive arterial disease. *Acta Orthop Scand* 1980; 51: 995–1006.
66. Hughes K, Domenig CM, Hamdan AD, Schermerhorn M, Aulivola B, Blattman S, Campbell DR, Scovell SD, LoGerfo FW, Pomposelli FB Jr. Bypass to plantar and tarsal arteries: an acceptable approach to limb salvage. *J Vasc Surg.* 2004 Dec;40(6):1149-57.
67. Jämsén T, Manninen H, Tulla H, Matsi P. The final outcome of primary infrainguinal percutaneous transluminal angioplasty in 100 consecutive patients with chronic critical limb ischemia. *J Vasc Interv Radiol.* 2002 May;13(5):455-63.
68. Johnson BL, Glickman MH, Bandyk DF, Esses GE. Failure of foot salvage in patients with end-stage renal disease after surgical revascularization. *J Vasc Surg.* 1995 Sep;22(3):280-5.
69. Kalra M, Gloviczki P, Bower TC, Panneton JM, Harmsen WS, Jenkins GD, Stanson AW, Toomey BJ, Canton LG. Limb salvage after successful pedal bypass grafting is associated with improved long-term survival. *J Vasc Surg.* 2001 Jan;33(1):6-16.
70. Leers SA, Reifsnnyder T, Delmonte R, Caron M. Realistic expectations for pedal bypass grafts in patients with end-stage renal disease. *J Vasc Surg.* 1998 Dec;28(6):976-80.
71. Lejay A, Georg Y, Tartaglia E, et al. Long-term outcomes of direct and indirect below-the-knee open revascularization based on the angiosome concept in diabetic patients with critical limb ischemia. *Ann Vasc Surg* 2014; 28: 983–9.
72. Mills JL, Gahtan V, Fujitani RM, Taylor SM, Bandyk DF. The utility and durability of vein bypass grafts originating from the popliteal artery for limb salvage. *Am J Surg.* 1994 Dec;168(6):646-50.
73. Mohan CR, Hoballah JJ, Martinasevic M, Chalmers RT, Sharp WJ, Kresowik TF, Corson JD. Revascularization of the ischemic diabetic foot using popliteal artery inflow. *Int Angiol.* 1996 Jun;15(2):138-43.

74. Owens CD, Ho KJ, Kim S, Schanzer A, Lin J, Matros E, Belkin M, Conte MS. Refinement of survival prediction in patients undergoing lower extremity bypass surgery: stratification by chronic kidney disease classification. *J Vasc Surg.* 2007 May;45(5):944-52
75. Panneton JM, Gloviczki P, Bower TC, Rhodes JM, Canton LG, Toomey BJ. Pedal bypass for limb salvage: impact of diabetes on long-term outcome. *Ann Vasc Surg.* 2000 Nov;14(6):640-7.
76. Pua U, Wong DE. Angioplasty in critical limb ischaemia: one-year limb salvage results. *Ann Acad Med Singapore.* 2008 Mar;37(3):224-9.
77. Ramdev P, Rayan SS, Sheahan M, Hamdan AD, Logerfo FW, Akbari CM, Campbell DR, Pomposelli FB Jr. A decade experience with infrainguinal revascularization in a dialysis-dependent patient population. *J Vasc Surg.* 2002 Nov;36(5):969-74.
78. Reed AB, Conte MS, Belkin M, Mannick JA, Whittemore AD, Donaldson MC. Usefulness of autogenous bypass grafts originating distal to the groin. *J Vasc Surg.* 2002 Jan;35(1):48-54.
79. Rigatelli G, Cardaioli P, Dell'avvocata F, Giordan M, Lisato G, Mollo F. Endovascular management of patients with coronary artery disease and diabetic foot syndrome: a long-term follow-up. *J Geriatr Cardiol* 2011; 8: 78–81.
80. Rosenblum BI, Pomposelli FB Jr, Giurini JM, Gibbons GW, Freeman DV, Chrzan JS, Campbell DR, Habershaw GM, LoGerfo FW. Maximizing foot salvage by a combined approach to foot ischemia and neuropathic ulceration in patients with diabetes. A 5-year experience. *Diabetes Care.* 1994 Sep;17(9):983-7.
81. Saltzberg SS, Pomposelli FB Jr, Belfield AK, Sheahan MG, Campbell DR, Skillman JJ, LoGerfo FW, Hamdan AD. Outcome of lower-extremity revascularization in patients younger than 40 years in a predominantly diabetic population. *J Vasc Surg.* 2003 Nov;38(5):1056-9.
82. Schneider JR, Walsh DB, McDaniel MD, Zwolak RM, Besso SR, Cronenwett JL. Pedal bypass versus tibial bypass with autogenous vein: a comparison of outcome and hemodynamic results. *J Vasc Surg.* 1993 Jun;17(6):1029-38.


83. Schneider PA, Caps MT, Ogawa DY, Hayman ES. Intraoperative superficial femoral artery balloon angioplasty and popliteal to distal bypass graft: an option for combined open and endovascular treatment of diabetic gangrene. *J Vasc Surg.* 2001 May;33(5):955-62.
84. Sigala F, Georgopoulos S, Langer S, Baunach C, Papalambros E, Sigalas K, Bramis J, Bakoyiannis C, Bastounis E, Hepp W. Outcome of infrainguinal revascularization for critical limb ischemia in diabetics with end stage renal disease. *Vasa.* 2006 Feb;35(1):15-20.
85. Söderström M, Arvela E, Albäck A, Aho PS, Lepäntalo M. Healing of ischaemic tissue lesions after infrainguinal bypass surgery for critical leg ischaemia. *Eur J Vasc Endovasc Surg.* 2008 Jul;36(1):90-5.
86. Stonebridge PA, Tsoukas AI, Pomposelli FB Jr, Gibbons GW, Campbell DR, Freeman DV, Miller A, LoGerfo FW. Popliteal-to-distal bypass grafts for limb salvage in diabetics. *Eur J Vasc Surg.* 1991 Jun;5(3):265-9.
87. Toursarkissian B, Jones WT, D'Ayala MD, Shireman PK, Harrison A, Schoolfield J, Sykes MT. Does the efficacy of dorsalis pedis artery bypasses vary among diabetic patients of different ethnic backgrounds? *Vasc Endovascular Surg.* 2002 May-Jun;36(3):207-12.
88. Toursarkissian B, Stefanidis D, Hagino RT, D'Ayala M, Schoolfield J, Shireman PK, Sykes MT. Early duplex-derived hemodynamic parameters after lower extremity bypass in diabetics: implications for mid-term outcomes. *Ann Vasc Surg.* 2002 Sep;16(5):601-7.
89. Verhelst R, Bruneau M, Nicolas AL, Frangi R, El Khoury G, Noirhomme P, Dion R. Popliteal-to-distal bypass grafts for limb salvage. *Ann Vasc Surg.* 1997 Sep;11(5):505-9.
90. Wallin L, Bjornsson H, Stenstrom A. Fluorescein angiography for predicting healing of foot ulcers. *Acta Orthop Scand* 1989; 60: 40–44.
91. Woelfle KD, Bruijnen H, Loeprecht H. Infrapopliteal arterial occlusive disease in diabetics with critical foot ischaemia: The role of distal origin bypass grafts. *Vasa* 2001; Suppl.58:40-43.

92. Woelfle KD, Lange G, Mayer H, Bruijnen H, Loeprecht H. Distal vein graft reconstruction for isolated tibioperoneal vessel occlusive disease in diabetics with critical foot ischaemia--does it work? *Eur J Vasc Surg*. 1993 Jul;7(4):409-13.
93. Wölfle KD, Bruijnen H, Reeps C, Reutemann S, Wack C, Campbell P, Loeprecht H, Häuser H, Bohndorf K. Tibioperoneal arterial lesions and critical foot ischaemia: successful management by the use of short vein grafts and percutaneous transluminal angioplasty. *Vasa*. 2000 Aug;29(3):207-14.
94. Zayed H, Halawa M, Maillardet L, Sidhu PS, Edmonds M, Rashid H. Improving limb salvage rate in diabetic patients with critical leg ischaemia using a multidisciplinary approach. *Int J Clin Pract*. 2009 Jun;63(6):855-8.
95. Zhan LX, Bharara M, White M, et al. Comparison of initial hemodynamic response after endovascular therapy and open surgical bypass in patients with diabetes mellitus and critical limb ischemia. *J Vasc Surg* 2012; 56: 380–6.

Table 1: List and summary of results for each item in the TOPS checklist. Change in score by year of publication tested using Spearman's rank correlation coefficient.

		Median	Percentage scoring (n)	Spearman Rho	P value
Study Design	Are appropriate definitions included for the terms "ulcer", "healing", and all other required aspects of the population and the outcomes		21 (16)	0.35	0.0015
	Was the choice of study population appropriate for the chosen intervention and the stated conclusions?		94 (73)	0.03	0.8079
	Was there a control population that was managed at the same time as those in the intervention group or groups?		3 (2)	-0.05	0.6716
	Is the intervention sufficiently well described to enable another researcher to replicate the study?		79 (62)	0.2	0.0778
	Are the components of other aspects described for the intervention and comparator groups?		21 (16)	0.16	0.1552
	Were the participants randomised into intervention and comparator groups?		0	NA	NA
	Were the participants randomised by an independent person or agency?		0	NA	NA
	Was the number of participants studied in the trial based on an appropriate sample size calculation?		1 (1)	0.04	0.7077
	Was the chosen primary outcome of direct clinical relevance?		17 (13)	0.17	0.1402
	Was the person who assessed the primary outcome or outcomes blinded to group allocation?		0	NA	NA
	Were either the clinical researcher who cared for the wound at research visits or the participants blinded to group allocation?		0	NA	NA
	Design Total Score	2		0.34	0.0023
Study Conduct	Did the study complete recruitment?		1 (1)	0.04	0.7077
	Was it possible to document the primary outcome in 75% or more of those recruited?		15 (12)	0.05	0.6748
	Were the results analysed primarily by ITT analysis?		6 (5)	-0.03	0.7923
	Were appropriate statistical methods used throughout?		94 (73)	-0.03	0.7923
	Was the performance in the control group of the order that would be expected in routine clinical practice?		0	NA	NA
	Are the results from all participating centres comparable? Answer "yes" if the study was done in only one centre.		92 (72)	-0.06	0.5761
	Conduct Total	2		-0.03	0.8132
Outcomes	Is the report free from errors of reporting - e.g., discrepancies between data reported in different parts of the report?		95 (74)	0.09	0.4369
	Are the important strengths and weaknesses of the study discussed in a balanced way?		51 (40)	0.44	>0.001
	Are the conclusions supported by the findings?		78 (61)	0.07	0.555
	Is the report free from any suggestion that the analysis or the conclusions could have been substantially influenced by people with commercial or other personal interests in the findings?		96 (75)	0.11	0.319
	Outcomes Total	3		0.35	0.0020
Overall	Total Score	8		0.39	0.0004764

Figure 1: Temporal relationship of TOP checklist score and year of publication of research articles appraised in the study. Separate graphs for overall TOP score and breakdown by checklist item domain into design, conduct and outcome.



Supplementary Appendix

Appendix 1: Raw data

Domains	Checklist Question	Aboyans 2008 ³⁴	Acin 2014 ²¹	AhChong 2004 ³⁸	Alexandrescu 2009 ¹⁵	Alexandrescu 2011 ³⁹	Apelqvist 2011 ⁵⁹	Bargellini 2008 ⁴²	Brechow 2009 ²⁶	Bunt 1980 ²⁵	Clairotte 2009 ²⁹	Davidson 1993 ⁶¹	Dorweiler 2002 ³²	Dosluoglu 2008 ³¹	Elgyri 2013 ²⁴	Elgyri 2014 ⁴³	Ezio 2010 ³⁰
Study Design	Are appropriate definitions included for the terms "ulcer", "heal	0	1	0	1	0	0	0	1	1	1	0	0	0	1	1	1
	Was the choice of study population appropriate for the chosen intervention and the stated conclusions?	1	1	1	1	1	1	1	1	1	0	1	1	1	1	1	1
	Was there a control population that was managed at the same time as those in the intervention group or groups?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Is the intervention sufficiently well described to enable another researcher to replicate the study?	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Are the components of other aspects described for the intervention and comparator groups?	0	0	0	1	1	0	0	1	0	0	0	1	1	0	0	0
	Were the participants randomised into intervention and comparator groups?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Were the participants randomised by an independent person or agency?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was the number of participants studied in the trial based on an appropriate sample size calculation?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was the chosen primary outcome of direct clinical relevance?	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	Was the person who assessed the primary outcome or outcomes blinded to group allocation?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Were either the clinical researcher who cared for the wound at research visits or the participants blinded to group allocation?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Study Conduct	Did the study complete recruitment?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was it possible to document the primary outcome in 75% or more of those recruited?	0	1	0	0	0	0	1	0	0	0	1	0	0	0	0	0
	Were the results analysed primarily by ITT analysis?	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0
	Were appropriate statistical methods used throughout?	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Was the performance in the control group of the order that would be expected in routine clinical practice?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Are the results from all participating centres comparable?	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Outcomes	Is the report free from errors of reporting - e.g., discrepancies between data reported in different parts of the report?	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Are the important strengths and weaknesses of the study discussed in a balanced way?	1	1	0	1	1	1	0	1	0	0	0	0	1	1	1	0
	Are the conclusions supported by the findings?	1	0	1	0	1	1	0	1	1	1	1	1	1	1	1	1
	Is the report free from any suggestion that the analysis or the conclusions could have been substantially influenced by people with commercial or other personal interests in the findings?	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Study Design		Cohort study	Case series	Case series	Case series	Cohort study	Cohort study	Case series	Cohort study	Cohort study	Cohort study	Case series	Case series	Case series	Cohort study	Cohort study	Cohort study
Total Score (/21)		8	8	7	10	8	8	9	10	8	7	8	8	9	9	9	8

Domains	Checklist Question	Faglia 2002 ¹⁶	Faglia 2005 ¹⁷	Faglia 2009 ¹⁸	Faris 1985 ⁶²	Ferraresi 2008 ³³	Gargiulo 2008 ¹⁹	Gershater 2008 ²⁷	Gibbons 1995 ⁴³	Hering 2010 ²⁰	Hertzner 2007 ⁶³	Holstein 1989 ⁶⁴	Hughes 2004 ⁶⁵	Isaksson 2000 ⁴⁴	Jämsén 2002 ⁶⁶	Johnson 1995 ⁶⁷	Kabra 2013 ³⁹	Kalani 2013 ⁴⁰
Study Design	Are appropriate definitions included for the terms "ulcer", "heal	1	1	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0
	Was the choice of study population appropriate for the chosen intervention and the stated conclusions?	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1
	Was there a control population that was managed at the same time as those in the intervention group or group?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Is the intervention sufficiently well described to enable another researcher to replicate the study?	1	1	1	1	1	1	1	1	1	1	0	1	1	1	1	1	1
	Are the components of other aspects described for the intervention and comparator groups?	0	1	1	0	1	0	1	0	0	0	0	0	0	0	0	1	1
	Were the participants randomised into intervention and comparator groups?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Were the participants randomised by an independent person or agency?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was the number of participants studied in the trial based on an appropriate sample size calculation?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was the chosen primary outcome of direct clinical relevance?	1	0	0	0	1	1	0	1	1	0	0	0	1	0	0	0	0
	Was the person who assessed the primary outcome or outcomes blinded to group allocation?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Were either the clinical researcher who cared for the wound at research visits or the participants blinded to group allocation?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Study Conduct	Did the study complete recruitment?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was it possible to document the primary outcome in 75% or more of those recruited?	1	0	0	0	1	1	0	1	1	0	0	0	1	0	0	0	0
	Were the results analysed primarily by ITT analysis?	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	Were appropriate statistical methods used throughout?	0	1	1	1	1	1	1	1	1	1	1	1	0	1	1	1	1
	Was the performance in the control group of the order that would be expected in routine clinical practice?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Are the results from all participating centres comparable? Answer "yes" if the study was done in only one centre.	0	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1
Outcomes	Is the report free from errors of reporting - e.g., discrepancies between data reported in different parts of the report?	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Are the important strengths and weaknesses of the study discussed in a balanced way?	0	1	1	1	1	0	1	0	0	0	0	1	1	0	1	0	1
	Are the conclusions supported by the findings?	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1	0	1
	Is the report free from any suggestion that the analysis or the conclusions could have been substantially influenced by people with commercial or other personal interests in the findings?	1	1	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1
Study Design		Case series	Case series	Cohort study	Cohort study	Case series	Case series	Cohort study	Case series	Case series	Case series	Cohort study	Case series	Case series	Case series	Case series	Case series	Cohort study
Total Score (/21)		8	10	10	8	11	10	9	8	10	7	6	8	9	7	8	6	9

Domains	Checklist Question	Kalra 2001 ⁶⁸	Kandzari 2006 ⁴⁵	Leers 1998 ⁶⁹	Lejay 2013 ⁷⁰	Lewis 2010 ⁵²	Liu 2013 ⁴¹	Malmstedt 2008 ¹⁴	Mills 1994 ⁷¹	Mohan 1996 ⁷²	Owen 2007 ⁷³	Panneton 2000 ⁷⁴	Parameswaran 2005 ⁵¹	Park 2013 ⁴⁸	Pomposelli 1995 ³⁴	Pomposelli 2003 ³⁵	Premalatha 2002 ⁵⁰
Study Design	Are appropriate definitions included for the terms "ulcer", "heal	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was the choice of study population appropriate for the chosen intervention and the stated conclusions?	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Was there a control population that was managed at the same time as those in the intervention group or groups?	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
	Is the intervention sufficiently well described to enable another researcher to replicate the study?	1	1	1	1	1	0	1	0	1	1	1	1	1	1	1	1
	Are the components of other aspects described for the intervention and comparator groups?	0	0	0	0	0	1	0	0	0	0	0	0	0	1	1	0
	Were the participants randomised into intervention and comparator groups?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Were the participants randomised by an independent person or agency?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was the number of participants studied in the trial based on an appropriate sample size calculation?	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	Was the chosen primary outcome of direct clinical relevance?	0	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0
	Was the person who assessed the primary outcome or outcomes blinded to group allocation?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Were either the clinical researcher who cared for the wound at research visits or the participants blinded to group allocation?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Study Conduct	Did the study complete recruitment?	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	Was it possible to document the primary outcome in 75% or more of those recruited?	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	Were the results analysed primarily by ITT analysis?	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	Were appropriate statistical methods used throughout?	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Was the performance in the control group of the order that would be expected in routine clinical practice?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Are the results from all participating centres comparable? Answer "yes" if the study was done in only one centre.	1	0	1	1	0	1	0	1	1	1	1	1	1	1	1	1
Outcomes	Is the report free from errors of reporting - e.g., discrepancies between data reported in different parts of the report?	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1
	Are the important strengths and weaknesses of the study discussed in a balanced way?	1	1	0	1	1	1	1	0	0	1	1	1	1	0	1	0
	Are the conclusions supported by the findings?	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1
	Is the report free from any suggestion that the analysis or the conclusions could have been substantially influenced by people with commercial or other personal interests in the findings?	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1
Study Design		Case series	Case series	Case series	Case series	Cross-sectional	Cross-sectional	Cohort study	Case series	Case series	Cohort study	Case series	Cross-sectional	Case series	Case series	Case series	Cross-sectional
Total Score (/21)		8	10	5	7	8	8	11	7	7	8	8	8	9	8	9	7

Domains	Checklist Question	Pua 2008 ⁷⁵	Ramdev 2002 ⁷⁶	Reed 2002 ⁷⁷	Rigatelli 2011 ⁷⁸	Rosenbaum 1994 ⁷⁹	Saltzberg 2003 ⁸⁰	Schneider 1993 ⁸¹	Schneider 2001 ⁸²	Sigala 2006 ⁸³	Soderstrom 2008 ⁸⁴	Söderström 2013 ⁸²	Stonebridge 1991 ⁸⁵	Tannenbaum 1992 ⁸⁶	Taylor 1987 ³⁷	Toursarkissian 2002 (1) ⁸⁶	Toursarkissian 2002 (2) ⁸⁷
Study Design	Are appropriate definitions included for the terms "ulcer", "heal	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	Was the choice of study population appropriate for the chosen intervention and the stated conclusions?	1	1	1	1	1	1	1	0	1	1	1	0	1	1	0	1
	Was there a control population that was managed at the same rate as those in the intervention group or group?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Is the intervention sufficiently well described to enable another researcher to replicate the study?	0	0	1	1	0	0	1	0	0	0	1	0	1	0	1	1
	Are the components of other aspects described for the intervention and comparator groups?	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0
	Were the participants randomised into intervention and comparator groups?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Were the participants randomised by an independent person or agency?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was the number of participants studied in the trial based on an appropriate sample size calculation?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was the chosen primary outcome of direct clinical relevance?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was the person who assessed the primary outcome or outcomes blinded to group allocation?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Were either the clinical researcher who cared for the wound at research visits or the participants blinded to group allocation?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Study Conduct	Did the study complete recruitment?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was it possible to document the primary outcome in 75% or more of those recruited?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Were the results analysed primarily by ITT analysis?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Were appropriate statistical methods used throughout?	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1
	Was the performance in the control group of the order that would be expected in routine clinical practice?	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Are the results from all participating centres comparable? Answer "yes" if the study was done in only one centre.	1	1	1	1	1	1	1	1	0	1	1	1	1	1	1	1
Outcomes	Is the report free from errors of reporting - e.g. discrepancies between data reported in different parts of the report?	0	1	1	1	1	1	1	1	0	1	1	1	1	1	1	1
	Are the important strengths and weaknesses of the study discussed in a balanced way?	1	0	0	0	0	0	0	0	0	1	1	0	1	0	1	1
	Are the conclusions supported by the findings?	1	1	1	0	0	0	1	0	0	1	1	0	1	0	1	1
	Is the report free from any suggestion that the analysts or the conclusions could have been substantially influenced by people with commercial or other personal interests in the findings?	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Study Design		Case series	Case series	Case series	Case series	Case series	Case series	Case series	Cohort study	Case series	Case series	Case series	Case series	Case series	Case series	Case series	Case series
Total Score (/21)		5	6	6	6	5	5	7	4	3	7	10	4	9	6	7	8

Domains	Checklist Question	Tsai 2013 ²⁸	Ucciolli 2010 ⁴⁶	Verhelst 1997 ⁹⁸	Vogelberg 1988 ⁵⁵	Wallin 2013 ⁸⁹	Werneck 2009 ⁴⁷	Williams 2005 ⁵³	Woelfe 2001 ⁹⁰	Woelffe 1993 ⁹¹	Wolffe 2000 ⁹²	Zayed 2009 ⁹³	Zhan 2012 ⁹⁴	Zhang 2009 ⁴⁹
Study Design	Are appropriate definitions included for the terms "ulcer", "heal	1	0	0	0	0	0	0	0	0	0	0	0	0
	Was the choice of study population appropriate for the chosen intervention and the stated conclusions?	1	1	1	1	1	1	1	1	1	1	1	1	1
	Was there a control population that was managed at the same rate as those in the intervention group or groups?	0	0	0	1	0	0	0	0	0	0	0	0	0
	Is the intervention sufficiently well described to enable another researcher to replicate the study?	1	1	0	1	1	1	1	1	0	1	0	1	1
	Are the components of other aspects described for the intervention and comparator groups?	0	0	0	0	0	0	0	0	0	0	0	0	0
	Were the participants randomised into intervention and comparator groups?	0	0	0	0	0	0	0	0	0	0	0	0	0
	Were the participants randomised by an independent person or agency?	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was the number of participants studied in the trial based on an appropriate sample size calculation?	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was the chosen primary outcome of direct clinical relevance?	0	1	0	0	0	1	0	0	0	0	0	0	0
	Was the person who assessed the primary outcome or outcomes blinded to group allocation?	0	0	0	0	0	0	0	0	0	0	0	0	0
	Were either the clinical researcher who cared for the wound at research visits or the participants blinded to group allocation?	0	0	0	0	0	0	0	0	0	0	0	0	0
Study Conduct	Did the study complete recruitment?	0	0	0	0	0	0	0	0	0	0	0	0	0
	Was it possible to document the primary outcome in 75% or more of those recruited?	0	1	0	0	0	0	0	0	0	0	0	0	0
	Were the results analysed primarily by ITT analysis?	0	0	0	0	0	0	0	0	0	0	0	0	0
	Were appropriate statistical methods used throughout?	1	1	1	1	1	1	1	1	1	1	0	1	1
	Was the performance in the control group of the order that would be expected in routine clinical practice?	0	0	0	0	0	0	0	0	0	0	0	0	0
	Are the results from all participating centres comparable?	1	1	1	1	1	1	1	1	1	1	1	1	1
	Answer "yes" if the study was done in only one centre.													
Outcomes	Is the report free from errors of reporting - e.g. discrepancies between data reported in different parts of the report?	1	1	0	1	1	1	1	1	1	1	1	1	1
	Are the important strengths and weaknesses of the study discussed in a balanced way?	1	1	0	0	0	1	0	0	0	0	0	1	1
	Are the conclusions supported by the findings?	1	1	0	0	1	0	1	1	0	1	1	1	1
	Is the report free from any suggestion that the analysts or the conclusions could have been substantially influenced by people with commercial or other personal interests in the findings?	1	1	1	1	1	1	1	1	1	1	1	1	1
Study Design		Cohort study	Case series	Case series	Cross-sectional	Cohort study	Case series	Cross-sectional	Case series	Case series	Case series	Case series	Case series	Case series
Total Score (/21)		9	10	4	7	7	8	7	7	5	7	5	8	8